U.S. markets closed
  • S&P 500

    4,063.04
    -89.06 (-2.14%)
     
  • Dow 30

    33,587.66
    -681.50 (-1.99%)
     
  • Nasdaq

    13,031.68
    -357.75 (-2.67%)
     
  • Russell 2000

    2,135.14
    -71.85 (-3.26%)
     
  • Crude Oil

    65.72
    +0.44 (+0.67%)
     
  • Gold

    1,815.90
    -6.90 (-0.38%)
     
  • Silver

    27.10
    -0.14 (-0.53%)
     
  • EUR/USD

    1.2076
    -0.0076 (-0.63%)
     
  • 10-Yr Bond

    1.6950
    +0.0710 (+4.37%)
     
  • GBP/USD

    1.4057
    -0.0087 (-0.61%)
     
  • USD/JPY

    109.6610
    +1.0410 (+0.96%)
     
  • BTC-USD

    54,420.20
    -2,035.33 (-3.61%)
     
  • CMC Crypto 200

    1,474.16
    -89.67 (-5.73%)
     
  • FTSE 100

    7,004.63
    +56.64 (+0.82%)
     
  • Nikkei 225

    28,147.51
    -461.08 (-1.61%)
     
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Coronavirus vaccine could add billions in value to this one stock

Brian Sozzi
·Editor-at-Large
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Gilead could be sitting on close to $20 billion in untapped stock market value, provided it has success with a potential new coronavirus vaccine.

Oppenheimer analyst Hartaj Singh estimates that a worldwide release of remdesivir — currently in Phase 3 trial for Gilead —could lead to $500 million in yearly “pandemic sales stocking.” The analyst assumes the coronavirus pill would cost $50 to $100 per patient compared to $16 a pill for flu treatment Tamiflu in the U.S. Singh sees the pill reaching 5 million to 10 million people in terms of pandemic stock-piling.

Gilead’s trials of remdesivir include one targeting patients with severe manifestations of coronavirus. The other focuses on patients with more moderate affects from COVID-19.

Gilead sign at headquarters in Silicon Valley. Gilead Sciences, Inc. is an American biotechnology company that researches, develops and commercializes drugs - Foster City, California, USA - 2020
Gilead sign at headquarters in Silicon Valley. Gilead Sciences, Inc. is an American biotechnology company that researches, develops and commercializes drugs - Foster City, California, USA - 2020

“Assuming such a conservative model, successful Phase 3 outcomes in the moderate patients are worth 5% to 10% to Gilead. If both Phase 3's are successful, we foresee greater pricing leverage in developed markets and higher stocking; leading to a 10% to 20% valuation bump. Clearly a pandemic stockpiling of remdesivir (like Tamiflu) is where Gilead stock benefits most. Acute treatment for millions of patients would be more a harbinger of a Street meltdown,” Singh writes.

Using the aggressive side of Singh’s estimates for remdesivir, Gilead’s market cap could approach $115 billion versus $94 billion today.

The market has begun to lock in on Gilead — and to a lesser extent Moderna — as coronavirus vaccine winners.

Shares of Gilead has rocketed 10% higher over the past month while the broader stock market has gone in the tank on fears of a global economic slowdown. On the other hand, Moderna — which has a coronavirus vaccine in Phase 1 — has seen its stock skyrocket 31% in the past month.

[Take our quick poll: Do you think the stock market has bottomed?]

Brian Sozzi is an editor-at-large and co-anchor of The First Trade at Yahoo Finance. Follow Sozzi on Twitter @BrianSozzi and on LinkedIn.

Read the latest financial and business news from Yahoo Finance

Follow Yahoo Finance on Twitter, Facebook, Instagram, Flipboard, SmartNews, LinkedIn, YouTube, and reddit.